论文部分内容阅读
目的:观察吸入沙美特罗与氟替卡松复合剂(舒利迭)治疗慢性阻塞性肺疾病(COPD)急性发作期的疗效。方法:选择COPD急性发作期58例,随机分为观察组28例和对照组30例。观察组在抗感染、祛痰、平喘等常规治疗的同时予舒利迭吸入,每次50μg/250μg,2次/d;对照组在抗感染、祛痰、平喘等常规治疗的同时予沙丁胺醇(万托林)吸入治疗。治疗7天后,比较两组治疗前后临床症状改善、血气分析、肺功能变化情况,并观察不良反应。结果:两组治疗后临床症状、血气情况、肺功能均有显著改善(P<0.05),但观察组疗效显著优于对照组(P<0.05)。结论:沙美特罗与氟替卡松复合剂治疗COPD急性发作期效果显著优于沙丁胺醇吸入治疗。
Objective: To observe the efficacy of inhaled salmeterol and fluticasone complex (seretide) in the treatment of acute exacerbation of chronic obstructive pulmonary disease (COPD). Methods: Fifty-eight COPD patients were randomly divided into observation group (n = 28) and control group (n = 30). The observation group was given inhaled seretide at the same time as conventional anti-infective, expectorant and anti-asthma treatment, 50μg / 250μg and 2 times / d each time. In the control group, anti-infective, expectorant and antiasthmatic were routinely treated Salbutamol (万 托林) inhalation therapy. After 7 days of treatment, the clinical symptoms, blood gas analysis and pulmonary function changes were compared between the two groups before and after treatment, and the adverse reactions were observed. Results: The clinical symptoms, blood gas and lung function of both groups were significantly improved after treatment (P <0.05), but the curative effect of the observation group was significantly better than that of the control group (P <0.05). Conclusions: Salmeterol and fluticasone are superior to albuterol inhalation in the treatment of acute exacerbation of COPD.